In this phase II Neo-PLANET study, we show that camrelizumab (an anti-PD-1 antibody) plus concurrent chemoradiotherapy is effective and safe as neoadjuvant therapy in patients with resectable locally advanced adenocarcinoma of the stomach or gastroesophageal junction (GEJ), with a pCR rate of 33.3% (95% confidence interval [CI], 18.6–51.0) in the full analysis set (FAS). This evidence concerns the gene PDCD1 and adenocarcinoma.